WallStreetZenWallStreetZen

NASDAQ: OABI
Omniab Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

OABI past revenue growth

How has OABI's revenue growth performed historically?
Company
72.28%
Industry
99.5%
Market
13.73%
OABI's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
OABI's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
OABI's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

OABI earnings and revenue history

Current Revenue
$66.1M
Current Earnings
-$26.6M
Current Profit Margin
-40.2%

OABI Return on Equity

Current Company
-8.5%
Current Industry
1.3%
Current Market
25.7%
OABI's Return on Equity (-8.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when OABI announces earnings.

OABI Return on Assets

Current Company
-6.9%
Current Industry
-1.5%
OABI is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

OABI Return on Capital Employed

Current Company
-8.02%
Current Industry
11.8%

OABI vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
OABI$66.12M-$11.52M-$26.60M+72.28%N/A
CABA$0.00-$52.58M-$57.46MN/AN/A
VERA$0.00-$104.74M-$107.35MN/AN/A
CDMO$150.30M$8.18M-$3.10M+30.88%N/A
TYRA$0.00-$50.22M-$50.56MN/AN/A
View Top Biotech Stocks

Omniab Earnings & Revenue FAQ

What were OABI's earnings last quarter?

Omniab (NASDAQ: OABI) reported Q2 2023 earnings per share (EPS) of -$0.15, up 25% year over year. Total Omniab earnings for the quarter were -$14.73 million. In the same quarter last year, Omniab's earnings per share (EPS) was -$0.12.

If you're new to stock investing, here's how to buy Omniab stock.

What was OABI's earnings growth in the past year?

As of Q3 2023, Omniab's earnings has grown year over year. Omniab's earnings in the past year totalled -$26.60 million.

What was OABI's revenue last quarter?

Omniab (NASDAQ: OABI) reported Q2 2023 revenue of $6.95 million up 3.51% year over year. In the same quarter last year, Omniab's revenue was $7.20 million.

What was OABI's revenue growth in the past year?

As of Q3 2023, Omniab's revenue has grown 72.28% year over year. This is 27.22 percentage points lower than the US Biotechnology industry revenue growth rate of 99.5%. Omniab's revenue in the past year totalled $66.12 million.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.